The validity of progression‐free survival 2 as a surrogate trial end point for overall survival-Reference-Cited by-同舟云学术

The validity of progression‐free survival 2 as a surrogate trial end point for overall survival

Published:2022-01-05 Issue:7 Volume:128 Page:1449-1457
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Woodford Rachel G.¹²^ORCID,Zhou Deborah D.‐X.³^ORCID,Kok Peey‐Sei¹^ORCID,Lord Sally J.¹^ORCID,Friedlander Michael⁴^ORCID,Marschner Ian C.¹^ORCID,Simes R. John¹^ORCID,Lee Chee Khoon¹²^ORCID

Affiliation:

1. National Health and Medical Research Council Clinical Trials CentreUniversity of Sydney Sydney New South Wales Australia

2. St George Cancer Care Centre Sydney New South Wales Australia

3. Chris O’Brien LifehouseRoyal Prince Alfred Hospital Sydney New South Wales Australia

4. Nelune Cancer Centre Prince of Wales Hospital and Prince of Wales Clinical School University of New South Wales Sydney New South Wales Australia

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.34085

Reference28 articles.

1. Confirmatory Trials in the Evaluation of Anticancer Medicinal Products in Man—PFS2: A Measure of Therapeutic Action-At-A-Distance

2. Progression-Free Survival Is a Surrogate for Survival in Advanced Colorectal Cancer

3. Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Subsequent management and outcomes after first-line PARP inhibitors progression in ovarian cancer patients;Journal of Ovarian Research;2024-04-01

2. Rapidly Evolving Pre- and Post-surgical Systemic Treatment of Melanoma;American Journal of Clinical Dermatology;2024-02-26

3. Validity and Efficiency of Progression-Free Survival-2 as a Surrogate End Point for Overall Survival in Advanced Cancer Randomized Trials;JCO Precision Oncology;2024-02

4. Real-world comparative effectiveness of palbociclib plus aromatase inhibitor in HR+/HER2- metastatic breast cancer;Future Oncology;2024-01-17

5. Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC;New England Journal of Medicine;2023-11-23